FI3811967T3 - Biologisesti aktiivisten kompleksien valmistus - Google Patents

Biologisesti aktiivisten kompleksien valmistus Download PDF

Info

Publication number
FI3811967T3
FI3811967T3 FIEP20208669.0T FI20208669T FI3811967T3 FI 3811967 T3 FI3811967 T3 FI 3811967T3 FI 20208669 T FI20208669 T FI 20208669T FI 3811967 T3 FI3811967 T3 FI 3811967T3
Authority
FI
Finland
Prior art keywords
salt
polypeptide
alpha
lactalbumin
seq
Prior art date
Application number
FIEP20208669.0T
Other languages
English (en)
Finnish (fi)
Inventor
Catharina Svanborg
Aftab Nadeem
Chin Shing Ho
Original Assignee
Hamlet Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamlet Pharma Ab filed Critical Hamlet Pharma Ab
Application granted granted Critical
Publication of FI3811967T3 publication Critical patent/FI3811967T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Inorganic Chemistry (AREA)
FIEP20208669.0T 2017-05-14 2018-05-14 Biologisesti aktiivisten kompleksien valmistus FI3811967T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes

Publications (1)

Publication Number Publication Date
FI3811967T3 true FI3811967T3 (fi) 2023-12-28

Family

ID=59201543

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20208669.0T FI3811967T3 (fi) 2017-05-14 2018-05-14 Biologisesti aktiivisten kompleksien valmistus

Country Status (13)

Country Link
US (3) US20200140481A1 (OSRAM)
EP (2) EP3811967B1 (OSRAM)
JP (2) JP7672122B2 (OSRAM)
KR (2) KR20260021814A (OSRAM)
CN (2) CN119700935A (OSRAM)
AU (1) AU2018269304B2 (OSRAM)
CA (1) CA3063285A1 (OSRAM)
DK (2) DK3618848T3 (OSRAM)
ES (2) ES2861252T3 (OSRAM)
FI (1) FI3811967T3 (OSRAM)
GB (1) GB201707715D0 (OSRAM)
PL (2) PL3618848T3 (OSRAM)
WO (1) WO2018210759A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2021032807A1 (en) * 2019-08-20 2021-02-25 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) * 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
CN120239612A (zh) 2022-10-03 2025-07-01 林南制药公司 一种用于治疗或预防癌症的包含α-乳清蛋白和脂肪酸或脂质的复合物
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
EP2643010B1 (en) 2010-11-24 2016-11-16 HAMLET Pharma AB Biologically active complex and its preparation
HUE038910T2 (hu) * 2012-08-09 2018-12-28 Hamlet Pharma Ab Profilaktikus és gyógytáp terápia
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Also Published As

Publication number Publication date
DK3811967T5 (da) 2024-08-19
JP7672122B2 (ja) 2025-05-07
JP2023075290A (ja) 2023-05-30
DK3618848T3 (da) 2021-03-01
EP3811967B1 (en) 2023-12-20
JP7705160B2 (ja) 2025-07-09
ES2973290T3 (es) 2024-06-19
PL3618848T3 (pl) 2021-06-14
AU2018269304A1 (en) 2019-11-21
WO2018210759A1 (en) 2018-11-22
PL3811967T3 (pl) 2024-03-18
KR20260021814A (ko) 2026-02-13
JP2020519673A (ja) 2020-07-02
EP3618848A1 (en) 2020-03-11
KR20200015557A (ko) 2020-02-12
CN110650746B (zh) 2024-12-31
ES2861252T3 (es) 2021-10-06
US12331073B2 (en) 2025-06-17
CA3063285A1 (en) 2018-11-22
EP3811967A1 (en) 2021-04-28
AU2018269304B2 (en) 2025-02-27
GB201707715D0 (en) 2017-06-28
US20260085088A1 (en) 2026-03-26
US20210130394A1 (en) 2021-05-06
EP3618848B1 (en) 2020-11-25
CN119700935A (zh) 2025-03-28
CN110650746A (zh) 2020-01-03
US20200140481A1 (en) 2020-05-07
DK3811967T3 (da) 2024-01-08

Similar Documents

Publication Publication Date Title
JP2020519673A5 (OSRAM)
JP2013079270A5 (OSRAM)
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
RU2017101436A (ru) Mic-1 слитные белки и их применение
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
CN107630060B (zh) 自组装胶原蛋白及其制备方法
JP2019504881A5 (OSRAM)
JP5437378B2 (ja) ヒャッポダ由来のヘモコアグラーゼ
RU2012131203A (ru) Технология изготовления макромолекулярных микросфер
HRP20130933T1 (hr) Pripravci sa smanjenom formacijom dimera
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
RU2016150678A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201500783A1 (ru) Способы получения дикетопиперазинов и соединений, содержащих дикетопиперазины
JP2016511238A5 (OSRAM)
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
CN107630059B (zh) 新型自组装胶原蛋白及制备方法
RU2014124143A (ru) Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
CN107630058B (zh) 一种新型自组装胶原蛋白及制备方法
ES2216181T5 (es) Procedimiento para preparar dimero purificado de factor derivado de hueso.
WO2015167003A1 (ja) コラーゲンまたはアテロコラーゲンの分解物、当該分解物の製造方法、および、当該分解物の利用
CN113061173A (zh) 一种分离αs1-酪蛋白的方法
CN102533917A (zh) 一种从胶原蛋白制备rgd活性多肽的方法
Kruzel et al. The alcohol-induced conformational changes in casein micelles: a new challenge for the purification of colostrinin
Fry et al. C-type natriuretic peptides
JP2019534858A5 (OSRAM)